YSYoshinobu Saito

Yoshinobu Saito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshinobu Saito has a total of 265 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

    by Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, et al.

    Background and Aim: Although nucleos(t)ide analog (NUC) therapy reduces hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients, HCC can develop despite viral suppression. Identifying predictive biomarkers of HCC during NUC therapy remains clinically important. This study aimed to identify novel biomarkers by proteomic analysis of serum extracellular vesicle (EV) proteins in CHB patients receiving NUC therapy. Methods: We enrolled 242 CHB patients treated with NUCs for over one year, with serum HBV DNA < 3.0 log IU/mL, no prior HCC, and available stored serum samples. Proteomic analysis of serum EV proteins was carried out to identify candidate biomarkers, followed by validation of their serum levels using enzyme‐linked immunosorbent assay (ELISA). Results: The median age was 55 years; 144 were male. During a median follow‐up of 10.1 years, 44 patients (18.2%) developed HCC. Five candidate EV proteins were identified: fibulin‐3, VCAM‐1, fibronectin, vWF, and FGFBP2. In univariate Cox analysis of serum levels of candidate EV proteins measured by ELISA, fibulin‐3 and VCAM‐1 were identified as significant predictive factors. In multivariate analysis, male sex, GGT, AFP, fibulin‐3, and the FIB‐4 index were independent predictors, whereas VCAM‐1 was not. A cutoff value for fibulin‐3 was set at 10.8 μg/mL. HCC incidence was significantly higher in patients with fibulin‐3 ≥ 10.8 μg/mL and in those with ≥ 3 of five identified risk factors. The 10‐year cumulative HCC incidence was 0% versus 37.2% in patients with 0 versus ≥ 3 risk factors. Conclusion: Serum fibulin‐3 is a novel biomarker predictive of HCC in CHB patients undergoing NUC therapy.

  • Open Access

    Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

    by Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori, et al.

    Aim: The effect of treatment response to anticoagulant therapy on prognosis of patients with cirrhosis and portal vein thrombosis (PVT) remains unclear. Methods: Forty‐one patients with cirrhosis and first PVT treated with intravenous anticoagulant therapy between January 2015 and April 2018 at 10 Japanese hospitals were included. Treatment response was defined based on change in size of PVT after anticoagulant therapy as the following: complete response (CR, 0%), partial response (PR, ≤ 50%), stable disease (SD, 51%–100%), and progressive disease (PD, ≥ 101%). CR and PR were combined as the effective group and SD and PD formed as the ineffective group. Results: The median age was 69 years, and 56% of the patients had Child–Pugh class B. Overall, 5 (12%) achieved CR, 22 (54%) achieved PR, 12 (29%) had SD and 2 (5%) had PD. During a median follow‐up of 31.8 months from the date of assessment of treatment response, 17 patients died. The overall survival rates at 1‐ and 3‐year were 82.5% and 65.1%, respectively. In the multivariate analysis, the model for end‐stage liver disease‐Na score was significantly associated with overall survival, whereas treatment response was not significant. Twenty‐five patients experienced liver‐related events with hospitalization, and the 3‐year cumulative rate of liver‐related events was 63.9%. In the multivariate analysis, treatment response was significantly associated with liver‐related events. The 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively ( p = 0.008). Conclusions: Among patients with cirrhosis, treatment response to anticoagulant therapy for PVT correlated with the incidence of liver‐related hospitalization events.

  • Open Access

    Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

    by Yuta Myojin, Hayato Hikita, Yuki Tahata, Kenji Fukumoto, Seiya Kato, Yoichi Sasaki, Shusuke Kumazaki, Atsunori Tsuchiya, Masaru Enomoto, Daiki Miki, et al.

    Background and Aims: Although direct‐acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates, the long‐term outcomes of patients with hepatitis C virus (HCV)‐related cirrhosis remain variable. Growth differentiation factor 15 (GDF15), a stress‐induced cytokine, has emerged as a potential biomarker for liver disease progression. This study aimed to evaluate the prognostic value of serum GDF15 levels in predicting hepatocellular carcinoma (HCC), hepatic decompensation, and mortality in patients with HCV‐related cirrhosis. Methods: We retrospectively analyzed 196 patients with HCV‐related cirrhosis who achieved SVR at 18 Japanese institutions. Serum GDF15 levels were measured at baseline (BL) and 24 weeks posttreatment (p24w). A previously validated cutoff of 1.75 ng/mL was applied. The clinical outcomes included HCC occurrence, hepatic decompensation, and all‐cause mortality. Results: During a median follow‐up of 46.2 months, 75 patients developed HCC, 28 experienced hepatic decompensation, and 25 died. Hepatic decompensation occurred significantly less frequently in the BL GDF15‐low group. Importantly, no deaths occurred in the GDF15‐low group, whereas the 5‐year survival rate in the GDF15‐high group was 71.7%. Similar trends were observed for GDF15 levels at p24w. In the overall cohort, GDF15 was not significantly associated with incident HCC; among HCC‐naïve patients, a nonsignificant trend toward lower 3‐year HCC incidence was observed in the GDF15‐low group. Conclusions: Serum GDF15 is a promising prognostic biomarker for post‐SVR outcomes in patients with HCV‐related cirrhosis. Its ability to predict decompensation and mortality through a validated cutoff supports its use for risk stratification and long‐term management in patients with chronic liver disease.


  • Open Access

    The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs

    by Kazuhiro Murai, Hayato Hikita, Ryoko Yamada, Yuki Nishimura, Masanori Miyazaki, Hisashi Ishida, Atsushi Hosui, Ryotaro Sakamori, Nobuyuki Tatsumi, Kazuyoshi Ohkawa, et al.

    Background and Aim: Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB). It is still uncertain whether the risk of incident hepatocellular carcinoma (HCC) continues beyond 5 or 10 years after the initiation of NUC treatment. We aimed to elucidate this in CHB patients receiving long‐term NUC treatment.Methods: This was a multicenter, observational study that included patients who began NUC treatment between July 2000 and March 2019; patients were retrospectively enrolled up to March 2019 and followed up until August 2024.Results: Among 737 CHB patients (156 with cirrhosis) who started NUC treatment, 147 developed HCC during a median follow‐up period of 144.2 months. The 5‐, 10‐, and 15‐year cumulative HCC rates were 11.2%, 18.4%, and 23.1%, respectively. Independent risk factors for subsequent HCC occurrence included older age, male sex, cirrhosis, low platelet count, low ALT levels, and high γ‐GTP levels at NUC initiation. After 5 years, the risk factors were cirrhosis, high γ‐GTP levels, and high AFP levels, whereas after 10 years, they were cirrhosis and diabetes. Landmark analysis revealed that the 5‐year cumulative HCC incidence was 8.1% at 5 years and 5.8% at 10 years after NUC initiation. In noncirrhotic patients, cumulative HCC incidence at 5 years was 5.8%, whereas 5‐year cumulative incidences starting at 5 and 10 years were 4.1% and 4.8%, respectively, remaining stable over time.Conclusion: The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation.


  • Top Cited Papers
    Open Access

    Hepatic stellate cells control liver zonation, size and functions via R-spondin 3

    by Atsushi Sugimoto, Yoshinobu Saito, Guanxiong Wang, Qiuyan Sun, Chuan Yin, Ki Hong Lee, Yana Geng, Presha Rajbhandari, Celine Hernandez, Marcella Steffani, et al.

    Hepatic stellate cells (HSCs) have a central pathogenetic role in the development of liver fibrosis. However, their fibrosis-independent and homeostatic functions remain poorly understood1–5. Here we demonstrate that genetic depletion of HSCs changes WNT activity and zonation of hepatocytes, leading to marked alterations in liver regeneration, cytochrome P450 metabolism and injury. We identify R-spondin 3 (RSPO3), an HSC-enriched modulator of WNT signalling, as responsible for these hepatocyte-regulatory effects of HSCs. HSC-selective deletion of Rspo3 phenocopies the effects of HSC depletion on hepatocyte gene expression, zonation, liver size, regeneration and cytochrome P450-mediated detoxification, and exacerbates alcohol-associated and metabolic dysfunction-associated steatotic liver disease. RSPO3 expression decreases with HSC activation and is inversely associated with outcomes in patients with alcohol-associated and metabolic dysfunction-associated steatotic liver disease. These protective and hepatocyte-regulating functions of HSCs via RSPO3 resemble the R-spondin-expressing stromal niche in other organs and should be integrated into current therapeutic concepts.


  • Open Access

    Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in mice

    by Shinnosuke Kudo, Hayato Hikita, Yoshinobu Saito, Kazuhiro Murai, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara

    The fine-tuned balance between anti-apoptotic Bcl-2 family proteins, such as Bcl-xL and Mcl-1, and pro-apoptotic Bcl-2 family proteins, like Bak and Bax, is crucial for maintaining hepatocyte integrity. BH3-only proteins, including Bid, Bim, Puma, Noxa, Bad, Bmf, Bik and Hrk, serve as apoptosis initiators. They are activated by various stimuli, which leads to Bak/Bax activation. We previously reported that Bid and Bim contributed to hepatocyte apoptosis through Bak/Bax activation in the absence of anti-apoptotic proteins Bcl-xL and/or Mcl-1. However, the comprehensive involvement of all eight BH3-only proteins in Bak/Bax-dependent hepatocyte apoptosis remains unclear. Puma disruption suppressed hepatocyte apoptosis in hepatocyte-specific Bcl-xL or Mcl-1 knockout (Bcl-xLΔHep/ΔHep or Mcl-1ΔHep/ΔHep) mice. Disruption of Bid and Bim partially prevented lethality in Mcl-1ΔHep/+ Bcl-xLΔHep/ΔHep mice, although severe hepatocyte apoptosis persisted, which was suppressed by additional Puma disruption. However, hepatocyte apoptosis was still induced compared to that in Mcl-1ΔHep/+ Bcl-xLΔHep/ΔHep BaxΔHep/ΔHep Bak−/− mice. Triple disruption of Bid, Bim and Puma did not prevent induction of hepatocyte apoptosis in tamoxifen-induced Mcl-1iΔHep/iΔHep Bcl-xLiΔHep/iΔHep mice. Primary hepatocytes, isolated from Mcl-1fl/fl Bcl-xLfl/fl Bid−/− Bim−/− Puma−/− mice and immortalized, underwent apoptosis with doxycycline-dependent Cre recombination. Among the remaining five BH3-only proteins, Bik and Hrk were not expressed in these cells, and Noxa knockdown, but not Bad or Bmf knockdown, reduced apoptosis. Noxa disruption alleviated hepatocyte apoptosis in Mcl-1ΔHep/ΔHep mice and tamoxifen-induced Mcl-1iΔHep/iΔHep Bcl-xLiΔHep/iΔHep Bid−/− Bim−/− Puma−/− mice, prolonging survival. Apoptosis persisted in immortalized primary hepatocytes isolated from Mcl-1fl/fl Bcl-xLfl/fl Bid−/− Bim−/− Puma−/− Noxa−/− mice where doxycycline-dependent Cre recombination was induced, but was completely suppressed by Bak/Bax knockdown, while Bad or Bmf knockdown had no effect. In conclusion, among the eight BH3-only proteins, Puma and Noxa, alongside Bid and Bim, contributed to Bak/Bax-dependent hepatocyte apoptosis, but not indispensably, in the absence of Mcl-1 and Bcl-xL.


  • Open Access

    Supplementary Figure from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis

    by Hayato Hikita, Takahiro Kodama, Satoshi Tanaka, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Satoshi Shimizu, Yoshito Hayashi, Wei Li, Minoru Shigekawa, et al.

    Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.

  • Open Access

    Sup Materials from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis

    by Hayato Hikita, Takahiro Kodama, Satoshi Tanaka, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Satoshi Shimizu, Yoshito Hayashi, Wei Li, Minoru Shigekawa, et al.

    Supplemental Figure legend and Material and Methods

  • Open Access

    Supplementary Figure 3 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis

    by Hayato Hikita, Takahiro Kodama, Satoshi Tanaka, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Satoshi Shimizu, Yoshito Hayashi, Wei Li, Minoru Shigekawa, et al.

    Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.

  • Open Access

    Supplementary Figure 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis

    by Hayato Hikita, Takahiro Kodama, Satoshi Tanaka, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Satoshi Shimizu, Yoshito Hayashi, Wei Li, Minoru Shigekawa, et al.

    Supplementary Figure 2. Bid deficiency suppresses hepatocyte apoptosis and oxidative stress in the livers of Mcl-1 KO mice.